Hypoparathyroidism Pipeline Summary

DelveInsight’s, “Hypoparathyroidism - Pipeline Insight, 2026” report provides comprehensive insights about 10 companies and 12+ pipeline drugs in Hypoparathyroidism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hypoparathyroidism: Understanding

Hypoparathyroidism: Overview

Hypoparathyroidism is an uncommon endocrine disorder characterized by dysfunction of the parathyroid glands, resulting in insufficient secretion of parathyroid hormone (PTH). Because PTH plays a key role in maintaining calcium and phosphate homeostasis, its deficiency leads to hypocalcemia and hyperphosphatemia, which can cause increased neuromuscular irritability. Patients may experience muscle cramps, spasms, twitching, paresthesia, seizures, and, in severe cases, tetany. The condition most commonly occurs following unintended removal or injury of the parathyroid glands during neck surgery, particularly thyroidectomy, although genetic, autoimmune, infiltrative, and other causes.

Hypoparathyroidism results from inadequate secretion or action of parathyroid hormone (PTH), which normally maintains calcium and phosphate balance in the body. Reduced PTH decreases calcium reabsorption in the kidneys, lowers the activation of vitamin D (calcitriol), and reduces calcium mobilization from bone, ultimately resulting in hypocalcemia. At the same time, reduced PTH decreases renal phosphate excretion, causing hyperphosphatemia. The combination of low calcium and high phosphate increases neuromuscular excitability and accounts for many of the clinical manifestations of hypoparathyroidism, including paresthesia, muscle cramps, spasms, and tetany.

The signs and symptoms of hypoparathyroidism are primarily related to hypocalcemia and increased neuromuscular excitability caused by inadequate parathyroid hormone (PTH) secretion. Patients may experience numbness and tingling (paresthesia), muscle cramps, muscle stiffness, twitching, and spasms, particularly involving the hands, feet, and face. More severe hypocalcemia can lead to tetany, seizures, laryngospasm, and cardiac abnormalities, including prolonged QT intervals and arrhythmias. Chronic hypoparathyroidism may also be associated with fatigue, anxiety, depression, cognitive difficulties, headaches, and visual disturbances due to cataracts. The severity of symptoms varies depending on the degree and duration of hypocalcemia.

Hypoparathyroidism is diagnosed primarily through biochemical evaluation, showing low serum calcium and inappropriately low or normal PTH levels. Additional findings may include elevated serum phosphate and low or normal magnesium levels. Diagnosis is supported by repeated measurements of calcium and PTH, while other laboratory tests, such as 25-hydroxyvitamin D, renal function, and urinary calcium, may help identify the underlying cause and assess complications.

Treatment of hypoparathyroidism primarily aims to maintain serum calcium levels and reduce symptoms of hypocalcemia. Conventional therapy includes oral calcium supplements and active vitamin D analogs, such as calcitriol, to improve calcium absorption. Magnesium deficiency should also be corrected, while thiazide diuretics may be used in selected patients with hypercalciuria. In patients who remain inadequately controlled with conventional therapy, parathyroid hormone replacement therapy may be considered.

"Hypoparathyroidism- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypoparathyroidism pipeline landscape is provided which includes the disease overview and Hypoparathyroidism treatment guidelines. The assessment part of the report embraces, in depth Hypoparathyroidism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypoparathyroidism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hypoparathyroidism R&D. The therapies under development are focused on novel approaches to treat/improve Hypoparathyroidism.

Hypoparathyroidism Emerging Drugs Chapters

This segment of the Hypoparathyroidism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypoparathyroidism Emerging Drugs

• Canvuparatide: MBX Biosciences

Canvuparatide (MBX 2109) is an investigational new drug (delivered via sub-cutaneous injection), that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism, or HP. Leveraging our proprietary PEP platform, we designed canvuparatide to treat the underlying pathophysiology of HP by providing a continuous, infusion-like exposure to parathyroid hormone, or PTH, with convenient once-weekly administration. Currently, the drug is in Phase III stage of its development for the treatment of Hypoparathyroidism.

• EXT608: Extend Biosciences

EXT608 is an investigational, long-acting parathyroid hormone (PTH) replacement therapy which is a modified form of PTH(1-34) designed to provide sustained activation of the PTH1 receptor (PTH1R) while extending the peptide’s circulation time through Extend Biosciences’ D-VITylation® technology, which attaches a vitamin D derivative to PTH and promotes reversible binding to vitamin D-binding protein, thereby reducing renal clearance. By activating PTH1R, EXT608 is intended to reproduce the physiological effects of endogenous PTH, including increasing renal calcium reabsorption, stimulating conversion of vitamin D to active calcitriol, enhancing calcium mobilization from bone, and increasing renal phosphate excretion. Currently, the drug is in Phase II stage of its development for the treatment of Hypoparathyroidism.

Further product details are provided in the report……..

Hypoparathyroidism: Therapeutic Assessment

This segment of the report provides insights about the different Hypoparathyroidism drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hypoparathyroidism

There are approx. 10+ key companies which are developing the therapies Hypoparathyroidism. The companies which have their Hypoparathyroidism drug candidates in the most advanced stage, i.e. Phase III include, MBX Biosciences, and others.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Hypoparathyroidism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypoparathyroidism: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypoparathyroidism therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypoparathyroidism drugs.

Hypoparathyroidism Report Insights

• Hypoparathyroidism Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hypoparathyroidism Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hypoparathyroidism drugs?
• How many Hypoparathyroidism drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypoparathyroidism?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypoparathyroidism therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hypoparathyroidism and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• MBX Biosciences
• Extend Biosciences
• Septerna Corporation
• Encellin

Key Products

• Canvuparatide
• EXT608
• SEP-479
• ENC-10x-xPTG